Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Colorectal Neoplasms 53Breast Neoplasms 53Neoplasms 40Advanced Solid Tumors 33Prostatic Neoplasms 31Multiple Myeloma 31Neoplasm Metastasis 29Recurrence 28Ovarian Neoplasms 28Lung Neoplasms 28Carcinoma, Hepatocellular 28Pancreatic Neoplasms 26Advanced Solid Tumor 21Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Lymphoma, Follicular 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Uterine Cervical Neoplasms 12Head and Neck Neoplasms 12Glioblastoma 12Lymphoma 11Solid Tumor 10Myasthenia Gravis 10

Interventions

atezolizumab 1Hydroxyurea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Treatment-Refractory Solid Tumors × Clear all
NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡